Topic:

M&A

Latest Headlines

Latest Headlines

New tax rules won't spook Mylan out of Abbott generics buy

A few potential deals have already caved under the weight of new U.S. tax rules that discourage inversion deals. Not Mylan's. The Pittsburgh-based company is pushing ahead with a $5.3 billion plan to buy a piece of Abbott Laboratories' overseas generics business--with a few edits, of course.

Private equity firm looks to unload sterilization services company for $1.5B

Med merger mania is leaving no stone unturned, even sterilization services. On the heels of Steris's bid for Britain's Synergy Health in another inversion deal, private equity firm GTCR is looking to unload Sterigenics International, another sterilization company, for $1.5 billion, including debt.

Siemens in talks to sell hearing aids biz for $2.6B+

On the heels of Siemens' sale of its healthcare IT and microbiology units, the company is eyeing a sale of its hearing aid unit to private equity firm EQT Partners AB for more than $2.6 billion.

Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.

Actavis, Sanofi, Boehringer jockey bids for OTC specialist Omega Pharma

Actavis seems to have a finger in every pie lately when it comes to pharma M&A, and rumor has it Omega Pharma's sales process is no exception.

Top investor bails on Valeant bid, backing Allergan-Shire combo instead

Valeant's takeover partner, Bill Ackman, is not slowing down in his pursuit to land a deal for Allergan. But a key investor may no longer be quite so gung-ho.

AbbVie faces stumbling blocks after cutting cord on $55B Shire deal

Days after AbbVie recommended that shareholders vote against its proposed $55 billion deal for Shire, the company officially cut the cord and terminated its pending merger. And while Shire has big plans to succeed solo, AbbVie could face a few stumbling blocks without the Dublin-based company by its side.

It's back to basics in M&A, and that's a good thing, Actelion CEO says

At least one potential tax-inversion buyout target is pretty happy about the new deal-quashing rules: Actelion CEO Jean-Paul Clozel. In fact, he says, the slap at inversions is not just good for him and Actelion, but for the whole pharma industry.

AbbVie's $55B deal for Shire is officially dead. Now what?

Shire and AbbVie have formally called it quits on a planned $55 billion merger, leaving each company to get by on the merits of its own pipeline and talk up the benefits of life without the other.

Left at the altar by AbbVie, Shire has cash, options and an M&A pedigree

While its merger with AbbVie is looking dead, Shire is likely in line for a $1.6 billion breakup fee, cash that could fund a major M&A push. And with renowned dealmakers in its executive ranks, Shire may not be lonely for long.